Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 10/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13032050 | 0.81 | GBA1 (0.42) | GAATHRBGBA1GBA2 | |
| SCHEMBL16187759 | 0.81 | DPP4 (0.42) | DPP4DPP8PREPFAPDPP9 | |
| SCHEMBL15372290 | 0.79 | GBA1 (0.44) | GAATHRBGBA1GBA2 | |
| SCHEMBL18922681 | 0.79 | GBA1 (0.44) | GAATHRBGBA1GBA2 | |
| SCHEMBL3317512 | 0.79 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL16279687 | 0.79 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL21292661 | 0.79 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL30064858 | 0.79 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL15186923 | 0.77 | GBA1 (0.42) | GAATHRBGBA1GBA2 | |
| SCHEMBL3360203 | 0.77 | GBA1 (0.42) | GAATHRBGBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS | 2015-08-20 | — | — | US | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140316124-A1 | MODIDIFED iRNA AGENTS | BANK OF AMERICA, N.A. | 2014-10-23 | — | — | US | disclosed |
| US-8796436-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | DPP4 4105/4885DPP8 2078/4885PREP 4401/4885 |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | DPP4 3648/4885DPP8 2888/4885PREP 3616/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | DPP4 3962/4885DPP8 2911/4885PREP 4740/4885 |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | DPP4 3648/4885DPP8 2888/4885PREP 3616/4885 |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | DPP4 4779/4885DPP8 4310/4885PREP 4271/4885 |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | DPP4 3648/4885DPP8 2888/4885PREP 3616/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | DPP4 3648/4885DPP8 2888/4885PREP 3616/4885 |
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | DPP4 3648/4885DPP8 2888/4885PREP 3616/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | DPP4 4779/4885DPP8 4310/4885PREP 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.